Showing results (271-280 of 655) with videos related to

Sort By:
Pageof 66
Chemotherapy|January 1, 1984
Antibiotic susceptibility of community hospital blood culture isolates of gram-negative bacilliR C Gordon, K J Tack, R I Haddy, et al.
Life Sciences|November 29, 2005
Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptorsB Schurad, R Horowski, S Jähnichen, et al.
Alimentary Pharmacology & Therapeutics|November 19, 2010
Risk factors for impaired health-related quality of life in functional dyspepsiaL Van Oudenhove, J Vandenberghe, R Vos, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2011
Effect of rimonabant on oesophageal motor function in manE Scarpellini, K Blondeau, V Boecxstaens, et al.
Clinical Therapeutics|May 20, 1998
Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study GroupK J Tack, T W Littlejohn, G Mailloux, et al.
International Journal of Clinical Practice|September 8, 2015
The impact of opioid-induced constipation among chronic pain patients with sufficient laxative useR J LoCasale, C J Datto, M K Margolis, et al.
Gastroenterology|May 29, 1999
Duodenogastroesophageal reflux and esophageal mucosal injury in mechanically ventilated patientsA Wilmer, J Tack, E Frans, et al.
Clinical Therapeutics|July 1, 1996
Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis. The Cefdinir Bronchitis Study GroupM J Sperling, A Puopolo, T J Griffin, et al.
Gastroenterology|May 29, 2001
Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordingsD Sifrim, R Holloway, J Silny, et al.
Expert Opinion on Pharmacotherapy|January 5, 2020
Current and emerging therapeutic options for the management of functional dyspepsiaA Vandenberghe, J Schol, K Van den Houte, et al.
Pageof 66